[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340511-105":59,"doc-detail-340511-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","leveraging-car-macrophages-targeting-c-met-for-precision-immunotherapy-in-pancreatic-cancer-insights-from-single-cell-multi-omics","Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer - insights from single-cell multi-omics","","Pancreatic cancer delivers poor prognosis and shows resistance to conventional therapies, driven in part by cancer stem cells (CSCs) and aggressive angiogenesis. This study applies single-cell multi-omics to develop a precision immunotherapy using chimeric antigen receptor (CAR) macrophages engineered to target the c-Met protein on pancreatic CSCs, aiming to couple CSC elimination with suppression of angiogenic signaling.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/leveraging-car-macrophages-targeting-c-met-for-precision-immunotherapy-in-pancreatic-cancer-insights-from-single-cell-multi-omics/340511/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/leveraging-car-macrophages-targeting-c-met-for-precision-immunotherapy-in-pancreatic-cancer-insights-from-single-cell-multi-omics/340511.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is c-Met considered a key target for pancreatic cancer CSCs in this study?","Question",{"text":113,"@type":114},"Single-cell RNA sequencing of pancreatic cancer tissue identified c-Met as a key marker of CSCs, supporting its use as the antigen target for CAR macrophages.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were CAR macrophages engineered and evaluated?",{"text":118,"@type":114},"CAR macrophages were engineered via a lentiviral system to express a c-Met-specific receptor. Their phagocytic efficiency against pancreatic CSCs was measured in vitro, and angiogenesis inhibition was also assessed, with in vivo efficacy evaluated in a mouse model.",{"name":120,"@type":111,"acceptedAnswer":121},"What outcomes did the CAR macrophages produce in vivo and in vitro?",{"text":122,"@type":114},"CAR macrophages showed high specificity for c-Met+ CSCs, increased phagocytosis, and reduced secretion of angiogenic factors such as VEGFA, FGF2, and ANGPT. In mice, they suppressed tumor growth and angiogenesis while prolonging survival.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340511,1790149122,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Hu etal. Molecular Medicine (2024) 30:231 Molecular Medicine  \n[https://doi.org/10.1186/s10020-024-00996-4](https://doi.org/10.1186/s10020-024-00996-4)  \nRESEARCH Open Access  \nLeveraging CAR macrophages targeting c-Met  for precision immunotherapy in pancreatic cancer: insights from single-cell multi-omics  \nLingyu Hu 1, Xiaoguang Wang 1, Zhengwei Song 1, Fei Chen 1 and Bin Wu 1*  \nAbstract  \nBackground Pancreatic cancer is known for its poor prognosis and resistance to conventional therapies, largely due to the presence of cancer stem cells (CSCs) and aggressive angiogenesis. Effectively targeting these CSCs and associated angiogenic pathways is crucial for effective treatment. This study leverages single-cell multi-omics to explore a novel therapeutic approach involving Chimeric Antigen Receptor (CAR) macrophages engineered to target the c-Met protein on pancreatic CSCs.  \nMethods We employed single-cell RNA sequencing to analyze pancreatic cancer tissue, identifying c-Met as a key marker of CSCs. CAR macrophages were engineered using a lentiviral system to express a c-Met-specific receptor. The phagocytic efficiency of these CAR macrophages against pancreatic CSCs was assessed in vitro, along with their ability to inhibit angiogenesis. The in vivo efficacy of CAR macrophages was evaluated in a mouse model of pancreatic cancer.  \nResults CAR macrophages demonstrated high specificity for c-Met + CSCs, significantly enhancing phagocytosis and reducing the secretion of angiogenic factors such as VEGFA, FGF2, and ANGPT. In vivo, these macrophages significantly suppressed tumor growth and angiogenesis, prolonging survival in pancreatic cancer-bearing mice. Conclusion CAR macrophages targeting c-Met represent a promising therapeutic strategy for pancreatic cancer, offering targeted elimination of CSCs and disruption of tumor angiogenesis. This study highlights the potential of single-cell multi-omics in guiding the development of precision immunotherapies.  \nKeywords Pancreatic cancer, CAR macrophages, c-Met, Single-cell multi-omics, Angiogenesis, Cancer stem cells  \n*Correspondence: Bin Wu [gdwkwb@zjxu.edu.cn](gdwkwb@zjxu.edu.cn)  \n1Department of Surgery, The Second Affiliated Hospital of Jiaxing University, No. 1518 North Huancheng Road, Jiaxing, Zhejiang 314000, People’s Republic of China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/l](http://creativecommons.org/l)icenses/by/4.0/.  \nHu et al. Molecular Medicine (2024) 30:231  \nIntroduction  \nPancreatic cancer, a highly malignant tumor, poses a significant clinical challenge due to its aggressive nature and poor prognosis (Tolliver et al. 2018; Omari et al. 2019). Globally, the incidence and mortality rates of pancreatic cancer are on the rise, making it a major threat to human health (Klein 2021; Sattar et al. 2021; Hu et al. 2021). Early diagnosis is particularly challenging as initial stages often lack clear symptoms, leading to late-stage diagnosis in most patients (Wood et al. 2022; Gao et al. 2023; Kartal et al. 2022). Moreover, the efficacy of conventional treatments, including surgery, chemotherapy, and radiotherapy, is limited due to the tumor’s unique microenvironment an","cbCainsGxmSurmHS","https://ap.wps.com/l/cbCainsGxmSurmHS","pdf",6425601,17,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"Why is c-Met considered a key target for pancreatic cancer CSCs in this study?\",\"answer\":\"Single-cell RNA sequencing of pancreatic cancer tissue identified c-Met as a key marker of CSCs, supporting its use as the antigen target for CAR macrophages.\"},{\"question\":\"How were CAR macrophages engineered and evaluated?\",\"answer\":\"CAR macrophages were engineered via a lentiviral system to express a c-Met-specific receptor. Their phagocytic efficiency against pancreatic CSCs was measured in vitro, and angiogenesis inhibition was also assessed, with in vivo efficacy evaluated in a mouse model.\"},{\"question\":\"What outcomes did the CAR macrophages produce in vivo and in vitro?\",\"answer\":\"CAR macrophages showed high specificity for c-Met+ CSCs, increased phagocytosis, and reduced secretion of angiogenic factors such as VEGFA, FGF2, and ANGPT. In mice, they suppressed tumor growth and angiogenesis while prolonging survival.\"}]","Leveraging CAR macrophages targeting c-Met for precision immunotherapy in pancreatic cancer - insights from single-cell multi-omics | PDF",1790036958,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/463471d8dd74081b667e48b5fd8b8057.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/40881971a91a45812ee6d871bb6e98d6.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2dd1e5a44bec8612a0e9bd817fe9c3d1.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/76594374dba768eb604004f21b3c6ab4.webp",980,1306]